Characterization of a novel BCHE "silent" allele: Point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium

Herve Delacour, Sofya Lushchekina, Isabelle Mabboux, Aurore Bousquet, Franck Ceppa, Lawrence M Schopfer, Oksana Lockridge, Patrick Masson

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype. Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing. Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate. Both catalytic parameters Km = 265 μM for BTC, two times higher than that of the atypical enzyme, and a low V max are consistent with the absence of activity against suxamethonium. Molecular dynamic (MD) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate. MD also showed that the enzyme volume is increased, suggesting a pre-denaturation state. This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.

Original languageEnglish (US)
Article numbere101552
JournalPloS one
Volume9
Issue number7
DOIs
StatePublished - Jul 23 2014

Fingerprint

suxamethonium
apnea
Butyrylthiocholine
Succinylcholine
Apnea
point mutation
Point Mutation
molecular dynamics
Molecular Dynamics Simulation
Alleles
alleles
Butyrylcholinesterase
Plasmas
Molecular dynamics
cholinesterase
Enzymes
enzymes
mutation
Mutation
Benzoylcholine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Characterization of a novel BCHE "silent" allele : Point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium. / Delacour, Herve; Lushchekina, Sofya; Mabboux, Isabelle; Bousquet, Aurore; Ceppa, Franck; Schopfer, Lawrence M; Lockridge, Oksana; Masson, Patrick.

In: PloS one, Vol. 9, No. 7, e101552, 23.07.2014.

Research output: Contribution to journalArticle

Delacour, Herve ; Lushchekina, Sofya ; Mabboux, Isabelle ; Bousquet, Aurore ; Ceppa, Franck ; Schopfer, Lawrence M ; Lockridge, Oksana ; Masson, Patrick. / Characterization of a novel BCHE "silent" allele : Point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium. In: PloS one. 2014 ; Vol. 9, No. 7.
@article{a411ceca552c447fa603ff687669f858,
title = "Characterization of a novel BCHE {"}silent{"} allele: Point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium",
abstract = "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a {"}silent{"} phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype. Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing. Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate. Both catalytic parameters Km = 265 μM for BTC, two times higher than that of the atypical enzyme, and a low V max are consistent with the absence of activity against suxamethonium. Molecular dynamic (MD) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate. MD also showed that the enzyme volume is increased, suggesting a pre-denaturation state. This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.",
author = "Herve Delacour and Sofya Lushchekina and Isabelle Mabboux and Aurore Bousquet and Franck Ceppa and Schopfer, {Lawrence M} and Oksana Lockridge and Patrick Masson",
year = "2014",
month = "7",
day = "23",
doi = "10.1371/journal.pone.0101552",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Characterization of a novel BCHE "silent" allele

T2 - Point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium

AU - Delacour, Herve

AU - Lushchekina, Sofya

AU - Mabboux, Isabelle

AU - Bousquet, Aurore

AU - Ceppa, Franck

AU - Schopfer, Lawrence M

AU - Lockridge, Oksana

AU - Masson, Patrick

PY - 2014/7/23

Y1 - 2014/7/23

N2 - Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype. Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing. Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate. Both catalytic parameters Km = 265 μM for BTC, two times higher than that of the atypical enzyme, and a low V max are consistent with the absence of activity against suxamethonium. Molecular dynamic (MD) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate. MD also showed that the enzyme volume is increased, suggesting a pre-denaturation state. This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.

AB - Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype. Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing. Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate. Both catalytic parameters Km = 265 μM for BTC, two times higher than that of the atypical enzyme, and a low V max are consistent with the absence of activity against suxamethonium. Molecular dynamic (MD) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate. MD also showed that the enzyme volume is increased, suggesting a pre-denaturation state. This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.

UR - http://www.scopus.com/inward/record.url?scp=84904609510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904609510&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0101552

DO - 10.1371/journal.pone.0101552

M3 - Article

C2 - 25054547

AN - SCOPUS:84904609510

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e101552

ER -